

Special Issue

Cancers: Molecular Imaging and Therapy

Message from the Guest Editor

We are pleased to announce a new Special Issue entitled 'Molecular Imaging and Therapy', to be published in *Cancers*, comprising a collection of articles from leading international experts on positron emission tomography/computed tomography (PET/CT) and radiopharmaceutical therapies for human solid tumours/cancers. The field of 'Theranostics', which is based on diagnostic and therapeutic radiopharmaceutical agents, is transforming the landscape of oncological imaging, promoting the development of treatments outside of conventional surgery/chemotherapy/radiation therapy and improving patient outcomes. This Special Issue aims to provide an updated overview of the evolving field of theranostics and discuss novel biomarkers, therapy approaches, opportunities and challenges in this exciting field encompassing cancer biology, imaging and therapy.

Guest Editor

Prof. Dr. Subramaniam Rathan

1. Dean's Office, Otago Medical School, University of Otago, Dunedin 9054, New Zealand
2. Department of Radiology, Duke University, Durham, NC 27708, USA

Deadline for manuscript submissions

closed (25 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149298

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)